<DOC>
	<DOC>NCT01140048</DOC>
	<brief_summary>This is a prospective, multicenter, observational study in participants who completed the 24-week, placebo-controlled MK-0476 Protocol 272 (NCT00076973) study of montelukast in the treatment of respiratory symptoms subsequent to RSV-induced bronchiolitis. The purpose of this study is to better understand the clinical and demographic correlates of asthma and atopic disorders in children (through the age of 6 years) with a history of severe RSV-induced bronchiolitis.</brief_summary>
	<brief_title>Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)</brief_title>
	<detailed_description />
	<mesh_term>Bronchiolitis</mesh_term>
	<criteria>successfully completed MK0476 Protocol 272 had RSVinduced bronchiolitis at entry into Protocol 272 had developed or had been diagnosed with any illness or congenital disorder that could be immediately life threatening</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Asthma</keyword>
</DOC>